1. Zhang, Yingchi, Gao, Yufeng, Zhang, Hui, Zhu, Xiaofan, Liu, Xin. 2018. PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. In Blood, 131, 2256-2261. doi:10.1182/blood-2017-11-817510. https://pubmed.ncbi.nlm.nih.gov/29434033/
2. Fayiga, Folasade F, Reyes-Hadsall, Sophia C, Moreno, Brian A, Brathwaite, Carole, Duarte, Ana M. 2023. Novel ANKRD26 and PDGFRB gene mutations in pediatric case of non-Langerhans cell histiocytosis: Case report and literature review. In Journal of cutaneous pathology, 50, 425-429. doi:10.1111/cup.14404. https://pubmed.ncbi.nlm.nih.gov/36753059/
3. Tzankov, Alexandar, Reichard, Kaaren K, Hasserjian, Robert P, Orazi, Attilio, Wang, Sa A. 2022. Updates on eosinophilic disorders. In Virchows Archiv : an international journal of pathology, 482, 85-97. doi:10.1007/s00428-022-03402-8. https://pubmed.ncbi.nlm.nih.gov/36068374/
4. Shima, Yasuyuki, Sasagawa, Shota, Ota, Nakao, Saito, Nobuhito, Nakatomi, Hirofumi. 2023. Increased PDGFRB and NF-κB signaling caused by highly prevalent somatic mutations in intracranial aneurysms. In Science translational medicine, 15, eabq7721. doi:10.1126/scitranslmed.abq7721. https://pubmed.ncbi.nlm.nih.gov/37315111/
5. Wang, Zhe, Liu, Ting, Liu, Wenbing, Mi, Yingchang, Wei, Shuning. 2023. A novel subclonal rearrangement of the STRN3::PDGFRB gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects. In Cancer gene therapy, 30, 1471-1484. doi:10.1038/s41417-023-00651-w. https://pubmed.ncbi.nlm.nih.gov/37550570/
6. Newman, Alexandra A C, Serbulea, Vlad, Baylis, Richard A, Cherepanova, Olga A, Owens, Gary K. 2021. Multiple cell types contribute to the atherosclerotic lesion fibrous cap by PDGFRβ and bioenergetic mechanisms. In Nature metabolism, 3, 166-181. doi:10.1038/s42255-020-00338-8. https://pubmed.ncbi.nlm.nih.gov/33619382/
智鼠故事 
